Skip to content
  • .
    • Global
    • France
    • Germany
    • UK
  • Contact Us
  • twitter
  • LinkedIn
gbt
  • Global
    • Global
    • France
    • Germany
    • UK
  • About
    • Our Company
    • Leadership
    • Board of Directors
    • Contact Us
  • Our Commitment
    • Patients & Advocacy
    • GBT’s Supported Conferences
    • COVID-19 Information and Resources
    • Corporate Giving
    • The GBT Foundation
    • Expanded Access
    • Environmental, Social and Governance
  • Research
    • Sickle Cell Disease
    • Pipeline
    • Externally Sponsored Research (ESR)
    • Partnerships
    • Publications
  • Our Medicine
  • Investors & Media
    • Company Summary
    • Media Resources
    • Press Releases
    • Events & Presentations
    • Quarterly Results
    • Analyst Coverage
    • Stock Information
    • SEC Filings
    • Governance
    • Investor FAQs
  • Careers
    • Jobs
  • Contact Us
  • twitter
  • LinkedIn
Hope

Hope is what feeds us,

connects us and moves us forward. It’s what we bring to life through access to innovative treatment and determined advocacy.

Learn more

Science

Science is our bedrock, our backbone.

It’s how we make good happen and find ways to answer significant unmet needs. It’s our promise.

Learn more
Community

Community is our strength and our inspiration.

Patients, their families and healthcare professionals are why we come to work each day and our reason for being.

Learn more
Advancing care in sickle cell diseaseAdvancing care in sickle cell disease

Advancing care in sickle cell disease

We are changing the way treatments for sickle cell disease are developed, approved and delivered

See our pipeline
Partnering with the communityPartnering with the community

Partnering with the community

Our deep commitment to the sickle cell community includes helping to create solutions to help improve the quality of care and access to treatment for patients

More on our commitment
Join our purpose-driven cultureJoin our purpose-driven culture

Join our purpose-driven culture

Every GBT colleague has an opportunity to make a difference for underserved patients

Build your career

June 16, 2022
Press Release

NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell Disease

June 13, 2022
Press Release

New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease

June 10, 2022
Press Release

GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease

June 6, 2022
Press Release

The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions

June 6, 2022
Press Release

GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease

View latest news
gbt

Copyright 2021
Global Blood Therapeutics, Inc.

  • Privacy Policy
  • Online Tracking Opt-Out Guide
  • Terms of use
  • Community guidelines

P-VOX-US-00501

  • About
    • Our Company
    • Leadership
    • Board of Directors
    • Contact Us
    • Careers
  • Our Commitment
    • Patients & Advocacy
    • GBT’s Supported Conferences
    • COVID-19 Information and Resources
    • Corporate Giving
    • The GBT Foundation
    • Expanded Access
    • Environmental, Social and Governance
  • Research
    • Sickle Cell Disease
    • Pipeline
    • Externally Sponsored Research (ESR)
    • Partnerships
    • Publications
  • Our Medicine
  • Investors & Media
    • Company Summary
    • Media Resources
    • Press Releases
    • Events & Presentations
    • Quarterly Results
    • Analyst Coverage
    • Stock Information
    • SEC Filings
    • Governance
    • Investor FAQs
  • Careers
    • Jobs
  • Contact Us
  • twitter
  • LinkedIn
This site uses cookies to give you the best online experience. Learn more, including how to disable certain cookies on our Privacy Page. Accept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
×

You are now leaving the Global Blood Therapeutics website

You are currently leaving our site. External links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Global Blood Therapeutics. Are you sure you want to proceed?